These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 19273671

  • 1. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
    Pruvost A, Negredo E, Théodoro F, Puig J, Levi M, Ayen R, Grassi J, Clotet B.
    Antimicrob Agents Chemother; 2009 May; 53(5):1937-43. PubMed ID: 19273671
    [Abstract] [Full Text] [Related]

  • 2. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens.
    Hawkins T, Veikley W, St Claire RL, Guyer B, Clark N, Kearney BP.
    J Acquir Immune Defic Syndr; 2005 Aug 01; 39(4):406-11. PubMed ID: 16010161
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
    Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR, Harris DR, Havens PL, Adolescent Trials Network for HIV/AIDS Interventions.
    Antimicrob Agents Chemother; 2008 Feb 01; 52(2):631-7. PubMed ID: 18025112
    [Abstract] [Full Text] [Related]

  • 4. Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients.
    Goicoechea M, Jain S, Bi L, Kemper C, Daar ES, Diamond C, Ha B, Flaherty J, Sun S, Richman D, Louie S, Haubrich R, California Collaborative Treatment Group.
    AIDS; 2010 Mar 13; 24(5):707-16. PubMed ID: 20087154
    [Abstract] [Full Text] [Related]

  • 5. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
    Waters LJ, Moyle G, Bonora S, D'Avolio A, Else L, Mandalia S, Pozniak A, Nelson M, Gazzard B, Back D, Boffito M.
    Antivir Ther; 2007 Mar 13; 12(5):825-30. PubMed ID: 17713166
    [Abstract] [Full Text] [Related]

  • 6. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.
    Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM, Delahunty T, Bushman LR, Fletcher CV.
    Clin Pharmacol Ther; 2008 Feb 13; 83(2):265-72. PubMed ID: 17597712
    [Abstract] [Full Text] [Related]

  • 7. SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.
    Campo R, DeJesus E, Bredeek UF, Henry K, Khanlou H, Logue K, Brinson C, Benson P, Dau L, Wang H, White K, Flaherty J, Fralich T, Guyer B, Piontkowsky D.
    Clin Infect Dis; 2013 Jun 13; 56(11):1637-45. PubMed ID: 23362296
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.
    Flynn PM, Mirochnick M, Shapiro DE, Bardeguez A, Rodman J, Robbins B, Huang S, Fiscus SA, Van Rompay KK, Rooney JF, Kearney B, Mofenson LM, Watts DH, Jean-Philippe P, Heckman B, Thorpe E, Cotter A, Purswani M, PACTG 394 Study Team.
    Antimicrob Agents Chemother; 2011 Dec 13; 55(12):5914-22. PubMed ID: 21896911
    [Abstract] [Full Text] [Related]

  • 9. Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.
    McComsey GA, Daar ES, O'Riordan M, Collier AC, Kosmiski L, Santana JL, Fichtenbaum CJ, Fink H, Sax PE, Libutti DE, Gerschenson M.
    J Infect Dis; 2013 Feb 15; 207(4):604-11. PubMed ID: 23204164
    [Abstract] [Full Text] [Related]

  • 10. Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults.
    Baheti G, King JR, Acosta EP, Fletcher CV.
    AIDS; 2013 Jan 14; 27(2):221-5. PubMed ID: 23032419
    [Abstract] [Full Text] [Related]

  • 11. Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.
    Gianotti N, Galli L, Poli A, Salpietro S, Nozza S, Carbone A, Merli M, Ripa M, Lazzarin A, Castagna A.
    Medicine (Baltimore); 2016 May 14; 95(22):e3780. PubMed ID: 27258510
    [Abstract] [Full Text] [Related]

  • 12. Lack of a significant drug interaction between raltegravir and tenofovir.
    Wenning LA, Friedman EJ, Kost JT, Breidinger SA, Stek JE, Lasseter KC, Gottesdiener KM, Chen J, Teppler H, Wagner JA, Stone JA, Iwamoto M.
    Antimicrob Agents Chemother; 2008 Sep 14; 52(9):3253-8. PubMed ID: 18625763
    [Abstract] [Full Text] [Related]

  • 13. Lopinavir/Ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy.
    Ofotokun I, Chuck SK, Binongo JN, Palau M, Lennox JL, Acosta EP.
    J Clin Pharmacol; 2007 Aug 14; 47(8):970-7. PubMed ID: 17615254
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.
    Vourvahis M, Davis J, Langdon G, Layton G, Fang J, Choo HW, Hansson AG, Tawadrous M.
    Antivir Ther; 2013 Aug 14; 18(6):745-54. PubMed ID: 23558061
    [Abstract] [Full Text] [Related]

  • 15. Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy.
    Bukkems VE, Smolders EJ, Jourdain G, Burger DM, Colbers AP, Cressey TR, PANNA Network and iTAP Study GroupDepartment of Pharmacy, Radboud Institute of Health Sciences (RIHS), Radboud University Medical Center, Nijmegen, The Netherlands..
    J Clin Pharmacol; 2021 Mar 14; 61(3):388-393. PubMed ID: 32960984
    [Abstract] [Full Text] [Related]

  • 16. Atazanavir pharmacokinetics with and without tenofovir during pregnancy.
    Mirochnick M, Best BM, Stek AM, Capparelli EV, Hu C, Burchett SK, Rossi SS, Hawkins E, Basar M, Smith E, Read JS, IMPAACT 1026s Study Team.
    J Acquir Immune Defic Syndr; 2011 Apr 15; 56(5):412-9. PubMed ID: 21283017
    [Abstract] [Full Text] [Related]

  • 17. First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting.
    Clumeck N, Mwamba C, Kabeya K, Matanda S, Vaira D, Necsoi C, Kadiebwe D, Delforge M, Kasamba E, Milolo C, Ilunga J, Kapend L.
    AIDS; 2014 May 15; 28(8):1143-53. PubMed ID: 25028911
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
    Bunupuradah T, Chetchotisakd P, Ananworanich J, Munsakul W, Jirajariyavej S, Kantipong P, Prasithsirikul W, Sungkanuparph S, Bowonwatanuwong C, Klinbuayaem V, Kerr SJ, Sophonphan J, Bhakeecheep S, Hirschel B, Ruxrungtham K, HIV STAR Study Group.
    Antivir Ther; 2012 May 15; 17(7):1351-61. PubMed ID: 23075703
    [Abstract] [Full Text] [Related]

  • 20. Abacavir/lamivudine versus tenofovir/emtricitabine with atazanavir/ritonavir for treatment-naive Japanese patients with HIV-1 infection: a randomized multicenter trial.
    Nishijima T, Takano M, Ishisaka M, Komatsu H, Gatanaga H, Kikuchi Y, Endo T, Horiba M, Kaneda S, Uchiumi H, Koibuchi T, Naito T, Yoshida M, Tachikawa N, Ueda M, Yokomaku Y, Fujii T, Higasa S, Takada K, Yamamoto M, Matsushita S, Tateyama M, Tanabe Y, Mitsuya H, Oka S, Epzicom-Truvada study team.
    Intern Med; 2013 May 15; 52(7):735-44. PubMed ID: 23545667
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.